The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have ...

Tyra Bioscience s announced the appointment of Bhavesh Ashar as Chief Operating Officer, effective December 1, 2025, succeeding Daniel Bensen who will become the Chief Discovery O ...

Johnson & Johnson's planned $3 billion acquisition of Halda Therapeutics is one of the largest deals for a CT-based biotech company.

SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies for ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a $3.48 billion market cap biopharmaceutical company with impressive gross margins of 93%, announced the results of its annual stockholders’ meeting held ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) ...

Julie Hambleton, a director at SpringWorks Therapeutics Inc . (NASDAQ:SWTX), recently sold shares valued at approximately $730,206, according to a recent SEC filing. The transaction involved the sale ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years ...

STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...